Key facts
- Quiver Bioscience’s last known valuation is $29.0M (Nov 2018).
- It has raised $54.4M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Pimlico Pond Investments, Exponential Capital (Atlanta), National Institutes of Neurological Disorders and Stroke, Porta (Beverages).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Quiver Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Quiver Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Quiver Bioscience
Developer of a neuroscience research platform designed to accelerate the discovery of therapeutics for central nervous system disorders. The company offers advanced human cellular models, measurement engineering, and artificial intelligence-driven analysis for neuronal activity and drug response, enabling life sciences researchers and pharmaceutical organizations to identify and develop therapeutics for chronic pain and neurodevelopmental disorders.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2013
- Employees
- 26
- Website
- quiverbioscience.com/
- Ownership
- Privately Held (backing)
Quiver Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quiver Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quiver Bioscience in its N-PORT filings yet. We sweep new filings monthly.